CA2750074A1 - Use of cardiotrophin-1 for the treatment of metabolic diseases - Google Patents
Use of cardiotrophin-1 for the treatment of metabolic diseases Download PDFInfo
- Publication number
- CA2750074A1 CA2750074A1 CA2750074A CA2750074A CA2750074A1 CA 2750074 A1 CA2750074 A1 CA 2750074A1 CA 2750074 A CA2750074 A CA 2750074A CA 2750074 A CA2750074 A CA 2750074A CA 2750074 A1 CA2750074 A1 CA 2750074A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- cardiotrophin
- activity
- treatment
- induces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100028892 Cardiotrophin-1 Human genes 0.000 title claims abstract 21
- 108010041776 cardiotrophin 1 Proteins 0.000 title claims abstract 21
- 208000030159 metabolic disease Diseases 0.000 title claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 14
- 102000004877 Insulin Human genes 0.000 claims abstract 7
- 108090001061 Insulin Proteins 0.000 claims abstract 7
- 229940125396 insulin Drugs 0.000 claims abstract 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 6
- 208000008589 Obesity Diseases 0.000 claims abstract 5
- 235000020824 obesity Nutrition 0.000 claims abstract 5
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 3
- 201000001421 hyperglycemia Diseases 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract 2
- 230000001235 sensitizing effect Effects 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 10
- 208000016097 disease of metabolism Diseases 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000002891 anorexigenic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001842 enterocyte Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900396 | 2009-02-12 | ||
| ESP200900396 | 2009-02-12 | ||
| PCT/ES2010/070072 WO2010092218A2 (es) | 2009-02-12 | 2010-02-10 | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2750074A1 true CA2750074A1 (en) | 2010-08-19 |
Family
ID=42562119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2750074A Abandoned CA2750074A1 (en) | 2009-02-12 | 2010-02-10 | Use of cardiotrophin-1 for the treatment of metabolic diseases |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110293562A1 (enExample) |
| EP (1) | EP2397152B1 (enExample) |
| JP (1) | JP2012517459A (enExample) |
| CN (1) | CN102316892B (enExample) |
| AU (1) | AU2010212794A1 (enExample) |
| BR (1) | BRPI1008415A2 (enExample) |
| CA (1) | CA2750074A1 (enExample) |
| ES (1) | ES2493618T3 (enExample) |
| MX (1) | MX2011008562A (enExample) |
| RU (1) | RU2011137413A (enExample) |
| WO (1) | WO2010092218A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11419916B2 (en) | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| CN106255748B (zh) * | 2014-02-24 | 2025-10-28 | 释放能量医药股份有限公司 | 诱导人褐色脂肪细胞祖细胞分化的方法和组合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| EP0179904A1 (en) | 1984-05-09 | 1986-05-07 | Medaphore Inc. | Oral insulin and a method of making the same |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US4992417A (en) | 1987-07-17 | 1991-02-12 | Mount Sinai School Of Medicine | Superactive human insulin analogues |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
| US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
| YU18596A (sh) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| PT1053020E (pt) | 1998-01-29 | 2004-06-30 | Poly Med Inc | Microparticulas absorviveis |
| JP2002523333A (ja) | 1998-07-31 | 2002-07-30 | ノボ ノルディスク アクティーゼルスカブ | Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用 |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| JP2005534345A (ja) * | 2002-07-29 | 2005-11-17 | エス セル インターナショナル ピーティーイー リミテッド | インスリン陽性、グルコース応答性細胞の分化のための多段階方法 |
| WO2005053728A2 (de) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik |
| GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
| WO2006097526A1 (en) * | 2005-03-17 | 2006-09-21 | Novo Nordisk A/S | Compounds for use in the treatment of obesity |
| TW200800920A (en) | 2006-02-15 | 2008-01-01 | Sanofi Aventis | Novel azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
-
2010
- 2010-02-10 WO PCT/ES2010/070072 patent/WO2010092218A2/es not_active Ceased
- 2010-02-10 CA CA2750074A patent/CA2750074A1/en not_active Abandoned
- 2010-02-10 MX MX2011008562A patent/MX2011008562A/es not_active Application Discontinuation
- 2010-02-10 EP EP10710061.2A patent/EP2397152B1/en active Active
- 2010-02-10 JP JP2011549615A patent/JP2012517459A/ja active Pending
- 2010-02-10 US US13/201,431 patent/US20110293562A1/en not_active Abandoned
- 2010-02-10 CN CN201080009256.9A patent/CN102316892B/zh not_active Expired - Fee Related
- 2010-02-10 AU AU2010212794A patent/AU2010212794A1/en not_active Abandoned
- 2010-02-10 ES ES10710061.2T patent/ES2493618T3/es active Active
- 2010-02-10 BR BRPI1008415-0A patent/BRPI1008415A2/pt not_active IP Right Cessation
- 2010-02-10 RU RU2011137413/15A patent/RU2011137413A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2397152B1 (en) | 2014-05-28 |
| JP2012517459A (ja) | 2012-08-02 |
| CN102316892A (zh) | 2012-01-11 |
| US20110293562A1 (en) | 2011-12-01 |
| MX2011008562A (es) | 2011-09-09 |
| WO2010092218A2 (es) | 2010-08-19 |
| BRPI1008415A2 (pt) | 2018-02-27 |
| RU2011137413A (ru) | 2013-03-20 |
| AU2010212794A1 (en) | 2011-08-11 |
| EP2397152A2 (en) | 2011-12-21 |
| WO2010092218A3 (es) | 2010-11-18 |
| CN102316892B (zh) | 2014-06-04 |
| ES2493618T3 (es) | 2014-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frias et al. | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial | |
| Wesson et al. | Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension | |
| KR102035879B1 (ko) | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 | |
| Tahrani et al. | Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus | |
| CN104981240B (zh) | 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途 | |
| Mahgoub et al. | An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus | |
| JP2011241213A5 (enExample) | ||
| EP3283115B1 (en) | Compositions for treating autism | |
| JP2010518164A5 (enExample) | ||
| AU2014207748B2 (en) | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders | |
| CA2750074A1 (en) | Use of cardiotrophin-1 for the treatment of metabolic diseases | |
| CN107660147A (zh) | 用于治疗帕金森病和相关障碍的组合物 | |
| Yoon et al. | Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials | |
| CN110339176A (zh) | 包含吉格列汀和二甲双胍的组合药物及其制备方法 | |
| Gallwitz | Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin | |
| Lukitasari et al. | 28 Green tea extract administration had a beneficial effect on ppar alpha and ppar gamma gene expression in metabolic syndrome rat model | |
| JP2012517459A5 (enExample) | ||
| KR20180053032A (ko) | 신규한 피페린 유도체 및 이를 포함하는 약학적 조성물 | |
| CN104906114A (zh) | 一种二甲双胍格列喹酮复方缓释胶囊及制备方法 | |
| Hoimark et al. | Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes | |
| Nugroho et al. | 29 DOSE-DEPENDENT EFFECTS OF GREEN TEA EXTRACT ON ADIPONECTIN LEVEL AND ADIPONECTIN RECEPTOR GENE EXPRESSION IN METABOLIC SYNDROME RAT MODELS | |
| KR20220119065A (ko) | 불면증 치료를 위한 렘보렉산트의 용도 | |
| Adnan | Type 2 diabetic patients fasting on Ramadan in Israel | |
| Kumar et al. | Optimizing Type 2 Diabetes Control with Nutraceuticals | |
| CN102391160A (zh) | 二甲双胍与2，5-二羟基苯磺酸盐以及二甲双胍与2，5-二羟基苯磺酸盐的复方组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20160210 |